Allometric prediction of the human pharmacokinetic parameters for naveglitazar.

Compounds that belong to the class known as dual (alpha,gamma) peroxisome proliferator-activated receptors (PPARs) show interesting pharmacological properties--regulation of blood glucose, fatty acids, and lipid parameters. Using the recently published preclinical data of naveglitazar, an allometric method was used to predict the human pharmacokinetic parameters (CL/F and Vss/F). The predicted parameters were compared to observed/predicted values of other important dual (a,y) PPAR compounds. The allometry data suggested that naviglitazar (CL/F) was at least 4 times faster than that of ragaglitazar, while the Vss was either equal to or 40% lower as compared to that of ragaglitazar.